EUVIMEDPoznaj EUVIMED
Open access

Antiarrhythmic effects of mirabegron on ventricular fibrillation in Langendorff‐perfused rabbit ventricles

Xiao Liu iD, Yen-Ling Sung, Liyang Zhang iD, Shuai Guo, Minjing Yang, James E Tisdale iD, Zhenhui Chen, Joshua I Goldhaber, Michael Rubart, Xiaochun Li, Peng-Sheng Chen iD

The Journal of Physiology · 2025

DOI: 10.1113/jp286901 ↗

At a glance

Journal article in The Journal of Physiology, 2025. Written by Xiao Liu and 10 co-authors. Institution: Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Major MEDLINE topics: Acetanilides, Thiazoles, Ventricular Fibrillation, Adrenergic beta-3 Receptor Agonists. Cited 3 times so far (Crossref); 54 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS, NIH HHS.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

β‐3 adrenoceptor (AR) counteracts the β‐1 and β‐2 ARs and rescues the effects of excessive catecholamines. To test the hypothesis that a β‐3 AR agonist (mirabegron) can reverse the effects of isoproterenol (ISO) on ventricular fibrillation (VF), we performed optical mapping studies in six male and six female Langendorff perfused rabbit hearts at baseline and after sequential administration of ISO (100 n m ), mirabegron (1000 n m ), apamin (100 n m ) and washout (Study I). An additional six male and six female hearts were studied with mirabegron doses ranging between 250 and 1000 n m without ISO (Study II). Patch clamp studies in human embryonic kidney 293 cells were performed to determine the effect of mirabegron on the apamin‐sensitive small conductance Ca 2+ activated K + current ( I KAS ). Study I show that ISO increased phase singularities per VF episode (PSs/VF) in females and the dominant frequency (DF) in both sexes. Mirabegron significantly decreased PSs/VF in both sexes and significantly decreased DF in females. Study II showed no significant difference in PSs/VF between sexes at mirabegron concentrations of 250 n m and 500 n m . However, females showed significantly lower PSs/VF than males at mirabegron concentrations of 750 n m and 1000 n m . There were no differences in the DF profiles of dose–response between males and females. Mirabegron did not inhibit or activate I KAS heterologously expressed in human embryonal kidney 293 cells. Reverse transcriptase‐quantitative PCR showed no differences in β‐3 AR expression between sexes. We conclude that mirabegron is antiarrhythmic, and its antiarrhythmic properties are more commonly observed in females than males. image Key points Sympathetic nerve activity activates β adrenoceptors to induce cardiac arrhythmia. Among the β adrenoceptors, β‐3 counteracts the effects of β‐1 and β‐2. Mirabegron is an US Food and Drug Administration (FDA)‐approved β‐3 agonist that does not by itself block cardiac ionic currents or prolong the QT interval. We showed that mirabegron significantly prevents wave breaks and reduces the dominant frequency of ventricular fibrillation. These effects are more prominent in female than in male rabbit ventricles. Because the FDA approves mirabegron for human use, its antiarrhythmic effects can be readily tested in humans.

Subjects

MeSH terms (MEDLINE)

AcetanilidesThiazolesVentricular FibrillationAdrenergic beta-3 Receptor AgonistsAnti-Arrhythmia AgentsHeart VentriclesAnimalsRabbitsMaleFemaleHumansHEK293 CellsIsoproterenol

Author keywords

IKASSK channelapaminbeta‐3 adrenoceptorion currentsoptical mappingpatch clampsex differences

Substances

mirabegronAcetanilidesThiazolesAdrenergic beta-3 Receptor AgonistsAnti-Arrhythmia AgentsIsoproterenol

Authors and institutions

  • Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • The Graduate Institute of Biomedical Optomechatronics, Taipei Medical University, Taipei, Taiwan.
  • Department of Pediatrics, Indiana University, Indianapolis, IN, USA.
  • College of Pharmacy, Purdue University, Indianapolis, IN, USA.
  • Division of Clinical Pharmacology, Department of Medicine, School of Medicine, Indiana University, Indianapolis, IN, USA.
  • the Krannert Cardiovascular Research Center and Division of Cardiology, Department of Medicine, Indiana University, Indianapolis, IN, USA.

ORCID profiles: Xiao Liu, Liyang Zhang, James E Tisdale, Peng-Sheng Chen

Funding

  • NHLBI NIH HHS
  • NIH HHS

Cite

APA

Liu, X., Sung, Y. L., Zhang, L., Guo, S., Yang, M., Tisdale, J. E., Chen, Z., Goldhaber, J. I., Rubart, M., Li, X., & Chen, P. S. (2025). Antiarrhythmic effects of mirabegron on ventricular fibrillation in Langendorff‐perfused rabbit ventricles. The Journal of Physiology. https://doi.org/10.1113/jp286901

Vancouver

Liu X, Sung YL, Zhang L, Guo S, Yang M, Tisdale JE, et al. Antiarrhythmic effects of mirabegron on ventricular fibrillation in Langendorff‐perfused rabbit ventricles. The Journal of Physiology. 2025. doi:10.1113/jp286901

BibTeX
@article{Liu2025,
  author = {Liu, Xiao and Sung, Yen-Ling and Zhang, Liyang and Guo, Shuai and Yang, Minjing and Tisdale, James E and Chen, Zhenhui and Goldhaber, Joshua I and Rubart, Michael and Li, Xiaochun and Chen, Peng-Sheng},
  title = {Antiarrhythmic effects of mirabegron on ventricular fibrillation in Langendorff‐perfused rabbit ventricles},
  journal = {The Journal of Physiology},
  year = {2025},
  doi = {10.1113/jp286901}
}
Start for free →